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BAKGROUND: The EVI1(ecotropic virus integration site 1) gene codes for a zinc-finger transcription factor, whose transcriptional
activation leads to a particularly aggressive form of acute myeloid leukaemia (AML). Although, EVI1 interactions with key proteins in
hematopoiesis have been previously described, the precise role of this transcription factor in promoting leukaemic transformation is
not completely understood. Recent works have identified specific microRNA (miRNA) signatures in different AML subgroups.
However, there is no analysis of miRNAs profiles associated with EVI1 overexpression in humans.
METHODS: We performed QT-RT–PCR to assess the expression of 250 miRNAs in cell lines with or without EVI1 overexpression and
in patient samples. We used ChIP assays to evaluated the possible binding of EVI1 binding to the putative miRNA promoter.
Proliferation of the different cell lines transfected with the anti- or pre-miRs was quantified by MTT.
RESULTS: Our data showed that EVI1 expression was significantly correlated with the expression of miR-1-2 and miR-133-a-1 in
established cell lines and in patient samples. ChIP assays confirmed that EVI1 binds directly to the promoter of these two miRNAs.
However, only miR-1-2 was involved in abnormal proliferation in EVI1 expressing cell lines.
CONCLUSIONS: Our data showed that EVI1 controls proliferation in AML through modulation of miR-1-2. This study contributes to
further understand the transcriptional networks involving transcription factors and miRNAs in AML.
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The human EVI1 (ecotropic virus integration site 1) gene is located
on 3q26.2, a region frequently rearranged in acute myeloid
leukaemia (AML) (Wieser, 2007). Most patients with 3q26
rearrangements overexpress EVI1. However, its expression is also
elevated in about 10% of AML patients with no 3q aberrations,
as a result of so far unknown mechanisms (Wieser, 2007). Of
importance, EVI1 overexpression associates with poor prognosis
and a shorter survival in AML (Nucifora et al, 2006).
MicroRNAs (miRNAs) are small non-coding RNAs that
negatively regulate gene expression by repressing translation or
inducing sequence-specific degradation of target mRNAs (Bartel,
2004). MicroRNAs play important roles in numerous cellular
processes including hematopoiesis (Shivdasani, 2006; Lawrie, 2007;
Fatica, 2006 no. 13). Over the past 3 years, several groups have
described miRNA signatures associated with recurrent cytogenetic,
molecular aberrations and with outcome in AML (Fabbri et al,
2008). However, anything is known about a miRNA profile in
human AML patients with 3q26 rearrangements or EVI1 over-
expression. It has been reported that miRNA regulation is
mediated by lineage-specific transcription factors involved in the
developmental and differentiation processes (Bartel, 2004; Choong
et al, 2007; Fazi et al, 2005). Interestingly, EVI1 and miRNAs
have important roles in development and cell differentiation
(Perkins et al, 1991). In this study, we establish a miRNA signature
in AML that could be possibly regulated by overexpression of
EVI1. We found a strong positive correlation between the
expression levels of EVI1 and clustered microRNAs miR-1-2/
133a-1 in AML cell lines and in patient samples. We demonstrated
that EVI1 binds to a region upstream of the miRNA cluster
resulting in an upregulation of miR-1-2/133a-1. Furthermore,
functional studies showed that expression of miR-1-2 was
associated with enhanced proliferation in AML.
MATERIALS AND METHODS
Cell lines and patient samples
Cell lines MUTZ-3, TF-1, F-36P, HEL, HL-60, NOMO-1, MOLM-13,
and OCI-AML2 were maintained in RPMI-1640, supplemented
with 1% penicillin-streptomycin, and 10% FBS (GIBCO-BRL,
Grand Island, NY, USA); 10ngml
–1 GM-CSF was added in
MUTZ-3, TF-1, and F-36P. P19 cell line was maintained in aMEM,
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ssupplemented wit 10% FBS. Patient samples were collected from
the Department of Genetics, University of Navarra, Spain
(Supplementary Table 1). Leukaemic blasts were obtained from
bone marrow of AML patients with more than 60% blasts. The
study was carried out in accordance with the ethical guidelines of
our institution.
Quantitative RT–PCR (qRT–PCR) of mRNA and miRNA
levels
Quantitative RT–PCR was carried out with ABI Prism-7500
(Applied Biosystems, Foster City, CA, USA) with 20ng of cDNA
using TaqMan gene expression assays for EVI1 (Hs01118675_m1)
and human GAPDH (Hs99999905_m1). Overexpression of EVI1
transcript was defined as levels higher than the average of seven
bone marrow samples from healthy volunteers and three times the
standard deviation. For miRNA quantification, qRT-PCR was
performed with 10ng of total RNA using either the TaqMan
miRNA Human Panel Assay Set (ED000298) or TaqMan miRNA
individual assays for miR-1-2 (002222), miR-133a-1 (002246), miR-
146b (001097), miR-155 (002623), miR-323 (000538), miR-379
(000568) and snRNA U6B (Applied Biosystems).
Western blot analysis
Nuclear or cytoplasmatic protein samples were resolved by
SDS–PAGE, electroblotted to a nitrocellulose membrane (Bio-
Rad, Hercules, CA, USA) and incubated with the appropriate
antibodies: anti-EVI1 (no. 2265, Cell Signaling), anti-lamA/C (no.
2032, Cell Signaling) and anti-b-tubulin (T4026, Sigma-Aldrich,
St Louis, MO, USA).
Chromatin immunoprecipitation assay
10 10
6 HEL cells were used with ChIP assay kit (Upstate,
Syracuse, NY, USA) according to the manufacturer instructions.
Protein–DNA complexes were immunoprecipitated overnight with
5mg of anti-EVI1 (C-20) mouse antibody (sc-8707-X, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Genomic regions containing
the EVI1-binding sites in the pre-miR-1-2 or pre-miR-133a-1
upstream regions (Ensembl 52 miRNA genes: ENSG00000207694
and ENSG00000207786) were amplified by PCR using specific
primers flanking the EVI1 binding sites: oligo no. 1 (forward),
50-aaacccaggtgctcacagac-30; oligo no. 1 (reverse), 50-cattccatagca
ttgtatgttca-30; oligo no. 2 (forward), 50-ttggcaatctgtacccaaaa-30;
oligo no. 2 (reverse), 50-tttcctgcgcttaatggttt-30. Quantification of
coimmunoprecipitated promoter fragments was performed in
triplicate using the SYBR-Green dye detection with oligos no. 1.
All-trans retinoic acid (ATRA) and DMSO treatments All-trans
retinoic acid (ATRA) and DMSO (Sigma-Aldrich) were used as
previously reported (Kazama et al, 1999). Cell morphology was
evaluated in conventional light-field microscopy.
Transfection assays P19 cells were transfected with siGENOME
siRNA D-006530-06 (Dharmacon, Lafayette, CO, USA) by Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA, USA) 48h after the
ATRA treatment; RNA was extracted 48h after transfection. For
miRNA functional assays, HEL or HL-60 cells were nucleofected
(Amaxa technology, Gaithersburg, MD, USA) with pre-miR-1-2
precursor (PM10617), pre-miR-1-2 inhibitor (AM10617), pre-miR-
133a-1 precursor (PM10413), pre-miR-133a-1 inhibitor (AM10413),
pre-miRNA, or anti-miRNA scrambled control (Applied Biosystems).
Statistical analysis
Class comparison and significant analysis of microarrays (SAMs)
were performed to identify differentially expressed miRNAs.
To make the analysis more restrictive and avoid false positives,
Po0.01 was interpreted to denote statistical significance.
To evaluate the correlation between EVI1 and miRNAs levels
expression in cell lines and patient samples we used
Spearman’s rank correlation coefficient because EVI1 values
lacked a normal distribution. DCt EVI1 (Ct EVI1-Ct GADPH)
and DCt miRNA (Ct miRNA-Ct snRNA U6B) were used
instead of raw data Ct as a way to normalise data. A value
of Po0.05 was interpreted to denote statistical significance.
Statistical analysis was performed using the SPSS 15.0 statistical
package.
RESULTS
To identify EVI1-miRNA signatures in AML, we choose eight cell
lines previously reported to be either positive or negative for EVI1
expression. We confirmed EVI1 expression at the mRNA and
protein level in these cell lines (Figure 1A and B) and we analysed
the expression levels of 250 mature miRNAs by qRT–PCR. After
raw data Ct normalisation, statistical analysis was performed by
class comparison and SAM to identify differentially expressed
miRNAs between the two groups. Several miRNAs were identified
by using each method, and six of them were common to both lists
(Figure 1C). Among these miRNAs, we found that miR-1-2 and
miR-133a-1 showed the highest correlation coefficient with EVI1
expression (R¼0.905 and R¼0.902, respectively) and the best
significance value (P¼0.002) (Figure 1D). Thus, we decided to
validate these two candidates in a cohort of 44 AML patient
samples (20 with EVI1 overexpression). We found a significant
correlation between the EVI1 mRNA and both miRNAs expression
levels (R¼0.772 and 0.695 for miR-1-2 and miR-133a-1, respec-
tively; Po0.001) (Figure 1E). Thus, EVI1 may be involved
in triggering or maintaining miR-1-2 and miR-133a-1 expression
in AML and favouring the perpetuation of the neoplastic
phenotype in these tumours.
miR-1-2 and miR-133a-1 are clustered together in the same loci
at chromosome 18 (Liu et al, 2007), suggesting that their
transcription might be regulated by similar mechanisms. To
elucidate whether EVI1 acts as a transcription factor for these two
microRNAs, we examine their putative promoters using bioinfor-
matics prediction tools. Interestingly, there were several binding
sites for EVI1 in the upstream regions of both miR-1-2 and
miR-133a-1 (Figure 2A). ChIP assays showed that EVI1 was bound
only to the region upstream miR-1-2, but not upstream miR-133a-1
(Figure 2B). The occupancy of this site by EVI1 was also confirmed
by qRT–PCR (Figure 2C).
The P19 cell line expresses EVI1 during ATRA-induced
neuroectodermal differentiation, but not during DMSO-induced
mesodermal. Thus, we assess whether EVI1 induction in this
model could also lead to miR-1-2/133a-1 expression. Consistently,
we could detect an increase in both EVI1 and miR-1-2/133a-1 levels
during ATRA-induced differentiation (Figure 2D). Importantly,
reducing the levels of EVI1 by siRNA resulted concomitant
decrease of these miRNAs (Figure 2E). Altogether, these data
suggest a positive regulation of miR-1-2 and miR-133a-1 expres-
sion by EVI1.
Finally, we wanted to elucidate whether modulation of expres-
sion levels of these two miRNAs would have a functional outcome
in AML cell lines. As EVI1 overexpression has been linked with
abnormal proliferation (Yuasa et al, 2005; Goyama et al, 2008)
first, we assessed this function. We found that inhibition of miR-1-2
in the EVI1-positive HEL cell line induced a significant decreased
in the proliferation potential of these cells. Interestingly, inhibition
of miR-133a-1 resulted in a moderately decreased in the
proliferation. When we transfected both of them together, we
observed an effect that was very similar to the one produced by the
antimiR-1 alone (Figure 2F). Of importance transfer of premiR-1,
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increased in the proliferation. However, transfer of premiR-133a-1
did not show any effect (Figure 2F). These data indicated that
miR-1 could be a critical regulator of proliferation in EVI1
overexpressing cell lines.
DISCUSSION
MicroRNAs have important roles in hematopoiesis, and also in the
molecular pathogenesis of AML (Fabbri et al, 2008). To date,
different miRNA signatures have been associated with defined
AML cytogenetic subgroups. However, even though there is
one study about miRNAs expression in relation with EVI1
overexpresssion in mice (Dickstein et al, 2010), there are no
studies analysing the differential miRNAs expression in AML
patients with EVI1 aberrant expression. Thus, this is the first study
describing a miRNA profile associated with EVI1 overexpression
in human AML. This EVI1-associated signature consists of six
different miRNAs, of which miR-1 and miR-133a-1 showed the
highest correlation with EVI1 levels in both cell lines and patient
samples. Interestingly, Marcucci et al (2010) reported the
upregulation of these two miRNAs in a set of AML patient with
normal karyotype and a mutation in IDH2, indicating a possible
role for these miRNAs in the malignant phenotype of AML
patients. We found that miR-1-2 expression was involved in
proliferation but not miR-133a-1. Nevertheless, we do not discard
the hypothesis that miR-133a-1 could be involved in other
functions such as inhibition of differentiation.
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Figure 1 EVI1 and miRNAs expression in AML. (A) Relative qRT–PCR quantification of EVI1 transcript expression in AML cell lines. The GADPH
levels were used as a normaliser for the calculation of the 2
 DDCt coefficient. (B) Immunoblot analysis of EVI1 protein levels in nuclear (NE) and cytosolic
fractions (CE). Lam A/C and tubulin levels serve as control for equal protein loading. (C) Identification of miRNAs differentially expressed
(Po0.01) between EVI1þ and EVI1– cell lines by class comparison and significant analysis of microarrays (SAM) methods. (D) Statistical analysis of miR-1-2
and miR-133a-1 expression levels in EVI1þ and EVI1  cell lines. (E) Spearman’s rank correlation coefficient between DCt EVI1 and DCt miR-1-2 or
miR-133a-1 in patient samples.
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standing of the role of EVI1 in AML. Our results demonstrate for
the first time a functional relationship between EVI1 and miRNAs
expression. Moreover, uncovers a new pathway that could lead
to the development of novel therapeutic approaches to treat
EVI1-overexpressing leukaemia patients.
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Figure 2 EVI1 controls proliferation through miR-1-2 modulation. (A) Schematic representation of EVI1-binding sites and PCR design in the
putative promoter of miR-1-2 and miR-133a-1.( B) The PCR amplification of EVI1-immunoprecipitated DNA with the oligos no. 1 and oligos no. 2.
Amplification of negative control (no DNA), input chromatin (input) and mock-immunoprecipitated chromatin (no Ab) were carried out as controls.
(C) Quantitative real-time PCR was performed with oligos no. 1. Input chromatin was used as a normaliser. Error bars represent standard deviation.
Results from a representative experiment, out of three, are shown. (D) Expression levels of mRNA EVI1, miR-1-2 and miR-133a-1 in cells treated with
DMSO 1% or ATRA 1mM relative to P19 control cells, b-actin and snRNA U6B levels were used as normalisers for mRNA and miRNAs
levels, respectively. (E) Quantification of mRNA EVI1, miR-1-2, and miR-133a-1 in P19 transfected with a scramble or an EVI1 siRNA, during the
ATRA treatment. (F) HEL and HL-60 cells were respectively transfected with premiRs or anti-miRs, as indicated, and cell proliferation was measured
at different time points. Untreated cells day 0 was given an arbitrary value of 1 and all the values were normalised with this group. Abbreviation:
a.u.¼arbitrary unit.
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